Featured Research

from universities, journals, and other organizations

Antiretroviral Therapy After Birth Decreases Mother-to-child HIV Transmission

Date:
October 10, 2003
Source:
Johns Hopkins University Bloomberg School Of Public Health
Summary:
Antiretroviral therapy given to babies after birth offers protection against HIV infection, according to researchers from the Johns Hopkins Bloomberg School of Public Health.

Antiretroviral therapy given to babies after birth offers protection against HIV infection, according to researchers from the Johns Hopkins Bloomberg School of Public Health.

They found that a regimen of nevirapine and zidovudine is 36 percent effective in blocking the transmission of HIV from mother to child. The researchers also report that giving these drugs to babies after birth is easier to administer when compared to giving antiretrovirals to mothers during pregnancy. <>p>"Short post-exposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1; NVAZ randomized clinical trial" is published in the October 11, 2003, issue of The Lancet.

Lead author Taha El Tahir Taha, MBBS, PhD, MPH, MCM, associate professor in the School's Department of Epidemiology, with a joint appointment in the Department of Population and Family Health Sciences, explained that nevirapine is typically given to mothers prior to delivery and to the baby after birth to prevent mother-to-child transmission of HIV. In Sub-Saharan Africa, most women arrive at medical facilities only a few hours before delivery and with an unknown HIV status, making it difficult to counsel them and test for HIV.

He said, "These factors limit the use of nevirapine before delivery. Another approach to prevent transmission of the disease is clearly necessary. In this study, we've shown that exposure after birth to prophylaxis with nevirapine and AZT can reduce mother-to-child transmission of HIV."

The researchers studied babies from 1,119 Malawian women with HIV-1 who presented late for delivery to determine if treatment with a combination of nevirapine and zidovudine as compared to a regimen of nevirapine alone reduced transmission of the disease. Infant HIV was tested at birth from cord blood samples and at 6-8 weeks. At the 6-8 week mark for babies who were HIV negative at birth, the protection rate was 7 percent for the 484 babies who received nevirapine and zidovudine and 12 percent for the 468 babies who received nevirapine only. The net reduction of overall mother-to-child transmission was five percent. These results are comparable to rates observed in studies in South Africa and Uganda, where antiretroviral drugs were given to both mother and infant.

The researchers also explain in their study that a regimen of nevirapine and zidovudine is easily given to babies orally immediately after birth a single dose of nevirapine followed by zidovudine twice a day for seven days. Giving post-exposure prophylaxis only to the baby is also easier than giving antiretrovirals to pregnant women and their newborns, especially in areas where resources are scare.

Dr. Taha said, "When it is not possible to give intrapartum nevirapine to the mother, it is still beneficial to give the intervention to the baby after birth. The baby will be afforded additional protection by receiving a second antiviral drug. With these new, promising results, we believe that alternative drugs may also be used as safety data become available. These regimens could also be extended to prevent transmission of HIV through breast milk."

Newton I. Kumwenda and Amanda Gibbons, both with the Johns Hopkins Bloomberg School of Public Health, co-authored the study. Additional co-authors were Robin L. Broadhead, Susan Fiscus, Valentino Lema, George Liomba, Chiwawa Nkhoma, Paolo G. Miotti and Donald R. Hoover.

###

Research was supported by grants from the Fogarty International Center, National Institutes of Health and the Doris Duke Charitable Foundation, N.Y.


Story Source:

The above story is based on materials provided by Johns Hopkins University Bloomberg School Of Public Health. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins University Bloomberg School Of Public Health. "Antiretroviral Therapy After Birth Decreases Mother-to-child HIV Transmission." ScienceDaily. ScienceDaily, 10 October 2003. <www.sciencedaily.com/releases/2003/10/031010075352.htm>.
Johns Hopkins University Bloomberg School Of Public Health. (2003, October 10). Antiretroviral Therapy After Birth Decreases Mother-to-child HIV Transmission. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2003/10/031010075352.htm
Johns Hopkins University Bloomberg School Of Public Health. "Antiretroviral Therapy After Birth Decreases Mother-to-child HIV Transmission." ScienceDaily. www.sciencedaily.com/releases/2003/10/031010075352.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins